Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.

NCT05630859 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

1004

Enrollment

INDUSTRY

Sponsor class

Conditions

Sexually Transmitted Diseases

Interventions

BIOLOGICAL: NgG low dose investigational vaccine
BIOLOGICAL: NgG medium dose investigational vaccine
BIOLOGICAL: NgG high dose investigational vaccine
BIOLOGICAL: Placebo
BIOLOGICAL: NgG HTD investigational vaccine
BIOLOGICAL: NgG below HTD investigational vaccine

Sponsor

GlaxoSmithKline